-
If you purchased shares of Roka Bioscience Inc (NASDAQ: ROKA), you might have certain options and should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Lawsuit Overview
Settlement Overview
You must register to view and download the Settlement Notice and Settlement Proof.
The settlement includes all persons, entities, or legal beneficiaries or participants in any entities who purchased or otherwise acquired Roka Bioscience Inc securities pursuant or traceable to Roka Bioscience Inc’s initial public offering, including those who bought or otherwise acquired Roka Bioscience Inc common stock during the period from July 17, 2014 through March 26, 2015.
November 8, 2017 - The court ordered the authorization of the distribution of the net settlement fund.
November 10, 2016 - The court approved the settlement.
June 28, 2016 - The court preliminarily approved the settlement.
August 25, 2015 - Defendants filed a motion to dismiss.
June 23, 2015 - The lead plaintiff filed an amended consolidated complaint.
April 21, 2015 - Lead plaintiff and lead counsel were appointed.
February 23, 2015 - Lead plaintiff motions were filed.
December 24, 2014 - An investor in shares of Roka Bioscience Inc (NASDAQ: ROKA) filed a lawsuit in the U.S. District Court for the District of New Jersey against Roka Bioscience Inc over alleged violations of Federal Securities Laws by Roka Bioscience in connection with certain allegedly false and misleading statements made between July 17, 2014 and November 6, 2014.
According to the complaint the plaintiff alleges on behalf of purchasers of Roka Bioscience Inc (NASDAQ: ROKA) common shares between July 17, 2014 and November 6, 2014, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that Roka Bioscience Inc 's initial public offering (“IPO”) documents allegedly failed to disclose known trends and uncertainties about the drastic decline in demand for its Atlas instruments that existed at the time of the IPO.
Roka Bioscience Inc reported that its annual Total Revenue rose from $0.10 million in 2012 to $2.18 million in 2013. Roka Bioscience Inc went public in July 2014 at $12 per share.
On November 6, 2014 Roka Bioscience Inc reported its third quarter 2014 financial results. Roka Bioscience reports a Net Loss for the third quarter was $9.1 million, or a loss of $(0.64) per share, compared with $9.4 million, or a loss of $(17.00) per share, for the same period in 2013. Additionally, Roka Bioscience Inc reported that there were no new Atlas® instruments placements made during the quarter. Shares of Roka Bioscience Inc (NASDAQ: ROKA) declined to as low as $2.97 per share on November 7, 2014.
On December 26, 2014, Roka Bioscience (NASDAQ: ROKA) shares closed at $4.47 per share.